Get started
Author

Jai Balkissoon

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
2011 · Douglas J. Schwartzentruber, David H. Lawson, et al. · New England Journal of Medicine · 935
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
2011 · M. Zweifel, G.C. Jayson, et al. · Annals of Oncology · 163
Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma
2013 · Julie A. Sosa, Rossella Elisei, et al. · Thyroid · 151
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
2010 · G J Rustin, G Shreeves, et al. · British Journal of Cancer · 134
PDF
Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors
2012 · Dan M. Patterson, Martin Zweifel, et al. · Clinical Cancer Research · 76
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
2016 · Bradley J. Monk, Michael W. Sill, et al. · Journal of Clinical Oncology · 70
A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
2016 · Edward B Garon, Jeffrey D Neidhart, et al. · OncoTargets and Therapy · 58
PDF
Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer
2012 · Julie A. Sosa, Jai Balkissoon, et al. · Surgery · 50
A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial.
2011 · J. A. Sosa, R. Elisei, et al. · Journal of Clinical Oncology · 40
Phase I Trial of Recombinant Human Macrophage Colony-Stimulating Factor Administered by Continuous Intravenous Infusion in Patients With Metastatic Cancer
1994 · D. J. Cole, M. G. Sanda, et al. · JNCI Journal of the National Cancer Institute · 34
Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate
2013 · Mohamed A Ibrahim, Diana V Do, et al. · BMC Pharmacology and Toxicology · 32
PDF
Massive upper gastrointestinal bleeding in a patient with a duodenal diverticulum: a case report and review of the literature.
1992 · J Balkissoon, B Balkissoon, et al. · PubMed Central · 29
Lymphatic mapping for staging of head and neck cancer
2004 · Jai Balkissoon, Barry M Rasgon, et al. · Seminars in Oncology · 24
Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial.
2010 · E. B. Garon, F. F. Kabbinavar, et al. · Journal of Clinical Oncology · 23
Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results
2009 · M. Zweifel, G. Jayson, et al. · Journal of Clinical Oncology · 18
A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): Analysis of safety and activity of the FALCON trial.
2011 · E. B. Garon, F. F. Kabbinavar, et al. · Journal of Clinical Oncology · 13
SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) + bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results.
2009 · E Mayer, M Kozloff, et al. · Cancer Research · 7
467 Updated efficacy and safety results for a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P) and bevacizumab (B) in stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC): The FALCON trial
2010 · E.B. Garon, J. Neidhart, et al. · European Journal of Cancer Supplements · 4
Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine (G) in patients (pts) with advanced solid tumors
2016 · V. Subbiah, A. Combest, et al. · European Journal of Cancer · 3
Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine (G) in pts with advanced solid tumors
2016 · V. Subbiah, A. Combest, et al. · Annals of Oncology · 2
PDF
P1.03-044 Exploratory Analysis of Lung Cancer Patients in a Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine
2017 · L. Bazhenova, R. Tran, et al. · Journal of Thoracic Oncology · 1
Using a data-driven approach to deliver complex studies in advanced therapeutics
2023 · Vito Romita, Jai Balkissoon · Immuno Oncology Insights
Solving challenges in cell therapy clinical trials & effectively delivering complex studies in advanced therapeutics
2023 · Jai Balkissoon, Vito Romita · Immuno Oncology Insights
PDF
Managing combination immunotherapy trials from a contract research organization's (CRO's) perspective.
2019 · Jai Balkissoon, Binh Nguyen, et al. · Journal of Clinical Oncology
Abstract A4: Combretastatin A-4 Phosphate (CA4P) is effective for the treatment of functional pancreatic neuroendocrine tumors (PNETs) in a transgenic mouse model.
2013 · Ziqiang Yuan, Nikolas Zaphiros, et al. · Molecular Cancer Therapeutics
Works count: 27
Citation count: 1,867
H-index: 15
I10-index: 16
Year
Topic
Type